JPRN-UMIN000008867已完成3 期
Placebo-controlled,double-blind,randomized study of comparing NK1 receptor antagonist/ palonosetoron/ dexamethasone on day 1+-dexamethasone on day2/3 in high emetogenic chemotherapy - DEX-1
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Hematopoietic malignancy (2) Known brain metastasis (3) Patients who cannot use cortico steroid (4) Patients taking systemic corticosteroid (topical and inhaled steroid are allowed). (5) Patients with a history of administration of highly emetogenic chemotherapy (6) Patients scheduled to receive moderately to highly emetogenic chemotherapy six days before and six after the day of highly emetogenic agent administration. (Minimally to low emetogenic agents are allowed). (7) Patients with history of or scheduled to receive radiation therapy to abdomen (below diagphram) or to pelvis from six days before chemotherapy to six days after chemotherapy. (8) Patient taking antiemetics other than study drug. (9) Patients who had a hypersensitivity reaction to NK1 receptor antagonist or palonosetoron or dexamethasone (10) Patients who are intolerant to chemotherapy (11) Pregnant, breastfeeding or expecting woman (12) Patients with uncontrolled diabetes (13) HBs are positive (14) Patients with active infection (15) Patients who are inappropriate to enter this study with any safety reasons, judged by the treating physician
研究者
相似试验
已完成
3 期
Randomized,double-blind,placebo-controlled study comparing formoterol-beclometason 12/200 mcg BID versus placebo to evaluate the improvement of coughing and quality of life in subjects with bronchiectasis.NL-OMON50523Erasmus MC, Universitair Medisch Centrum Rotterdam72
进行中（未招募）
1 期
Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumoniaP. aeruginosa pneumoniaMedDRA version: 19.1 Level: PT Classification code 10035664 Term: Pneumonia System Organ Class: 10021881 - Infections and infestationsEUCTR2016-004261-10-ESAridis Pharmaceuticals, Inc.108
进行中（未招募）
1 期
Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumoniaMedDRA version: 20.0 Level: PT Classification code 10035664 Term: Pneumonia System Organ Class: 10021881 - Infections and infestationsPseudomonas aeruginosa pneumoniaEUCTR2016-004261-10-GRAridis Pharmaceuticals, Inc.154
进行中（未招募）
1 期
Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumoniaPseudomonas aeruginosa pneumoniaEUCTR2016-004261-10-CZAridis Pharmaceuticals, Inc.154
进行中（未招募）
1 期
Placebo-controlled, double-blind, randomized study of Aerucin® asadjunct therapy to antibiotics in the treatment of P. aeruginosapneumoniaPseudomonas aeruginosa pneumoniaEUCTR2016-004261-10-BEAridis Pharmaceuticals, Inc.154